

# Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Pipeline Review, H1 2018

<https://marketpublishers.com/r/PEE54C94F35EN.html>

Date: March 2018

Pages: 73

Price: US\$ 3,500.00 (Single User License)

ID: PEE54C94F35EN

## Abstracts

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Pipeline Review, H1 2018

### SUMMARY

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) pipeline Target constitutes close to 12 molecules. The latest report Placenta Growth Factor - Pipeline Review, H1 2018, outlays comprehensive information on the Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Placental growth factor is a protein encoded by the PGF gene. Placental growth factor (PGF) is a member of the VEGF (vascular endothelial growth factor). It plays an important role in angiogenesis and endothelial cell growth, stimulating their proliferation and migration.

It binds to the receptor FLT1/VEGFR-1. PGF is also expressed in many other tissues, including the villous trophoblast. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 2, 5 and 3 respectively.

Report covers products from therapy areas Ophthalmology, Metabolic Disorders and Oncology which include indications Wet (Neovascular/Exudative) Macular

Degeneration, Diabetic Macular Edema, Diabetic Retinopathy, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Choroidal Neovascularization, Retinal Vein Occlusion, Diabetic Nephropathy, Macular Edema, Medulloblastoma, Myopia, Neovascular Glaucoma, Non-Proliferative Diabetic Retinopathy (NPDR), Optic Neuropathy and Retinopathy.

Furthermore, this report also reviews key players involved in Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)

The report reviews Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics and enlists all their major and minor projects

The report assesses Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics based on mechanism of

action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) -  
Overview

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) -  
Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) -  
Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) -  
Companies Involved in Therapeutics Development

Alteogen Inc

Benitec Biopharma Ltd

Chengdu Kanghong Pharmaceuticals Group Co Ltd

Coherus BioSciences Inc

Formycon AG

Lupin Ltd

Regeneron Pharmaceuticals Inc

ThromboGenics NV

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) -  
Drug Profiles

(afibercept + nesvacumab) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

afibercept - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

afibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action  
R&D Progress  
aflibercept biosimilar - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
aflibercept biosimilar - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
aflibercept biosimilar - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
aflibercept SR - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
BB-201 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
conbercept - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
SL-186 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
SL-188 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
THR-317 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
ziv-aflibercept - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) -

Dormant Products

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) -

Discontinued Products

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) -

Product Development Milestones

Featured News & Press Releases

Mar 19, 2018: EYLEA (aflibercept) Injection Demonstrates Positive Top line Results in Phase 3 Non-Proliferative Diabetic Retinopathy Trial

Feb 13, 2018: Bayer Receives First Approval for Eylea in China

Feb 12, 2018: New data for aflibercept show prolonged injection intervals

Dec 21, 2017: Bayer Yakuhin Announces Results on EYLEA at the 11th Asia Pacific Retinal Vitreological Society (APVRS)

Dec 11, 2017: Regeneron Announces FDA Acceptance of sBLA Filing for 12-Week Dosing of EYLEA (aflibercept) Injection for Patients with Wet AMD

Nov 27, 2017: Regeneron Provides Update on Eylea (Aflibercept) Injection and Nesvacumab (Ang2 Antibody) Combination Program

Oct 09, 2017: ThromboGenics announces publication in Experimental Eye Research of preclinical data supporting therapeutic potential of THR-317 in DR

Sep 22, 2017: NICE gives EYLEA the Green Light for Treating Visual Impairment Due to mCNV

Aug 30, 2017: Bayer to showcase latest Ophthalmology research at EURETINA 2017

Jul 10, 2017: New use of drug could reduce need for laser treatment in diabetes

May 24, 2017: ThromboGenics to present THR-317 Pre-clinical Research Findings at the European Association for the Study of Diabetes, Eye Complications Study Group Meeting in Budapest, Hungary

May 09, 2017: The first UK trial comparing intravitreal aflibercept and laser for proliferative diabetic retinopathy reports at ARVO 2017

Feb 02, 2017: Benitec Biopharma makes significant progress in ocular program

Jan 17, 2017: ONCURIOUS Announces European Commission Confirmed Orphan Medicinal Product Designation for TB-403 for Medulloblastoma

Jan 10, 2017: ThromboGenics Enrolls First Patients in Phase II Clinical Study Evaluating THR-317 (Anti-PIGF) for Diabetic Macular Edema

Appendix

Methodology

Coverage

Secondary Research  
Primary Research  
Expert Panel Validation  
Contact Us  
Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2018  
Number of Products under Development by Therapy Areas, H1 2018  
Number of Products under Development by Indication, H1 2018  
Number of Products under Development by Companies, H1 2018  
Products under Development by Companies, H1 2018  
Products under Development by Companies, H1 2018 (Contd.1), H1 2018  
Number of Products by Stage and Mechanism of Actions, H1 2018  
Number of Products by Stage and Route of Administration, H1 2018  
Number of Products by Stage and Molecule Type, H1 2018  
Pipeline by Alteogen Inc, H1 2018  
Pipeline by Benitec Biopharma Ltd, H1 2018  
Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, H1 2018  
Pipeline by Coherus BioSciences Inc, H1 2018  
Pipeline by Formycon AG, H1 2018  
Pipeline by Lupin Ltd, H1 2018  
Pipeline by Regeneron Pharmaceuticals Inc, H1 2018  
Pipeline by ThromboGenics NV, H1 2018  
Dormant Projects, H1 2018  
Discontinued Products, H1 2018



## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

### COMPANIES MENTIONED

Alteogen Inc

Benitec Biopharma Ltd

Chengdu Kanghong Pharmaceuticals Group Co Ltd

Coherus BioSciences Inc

Formycon AG

Lupin Ltd

Regeneron Pharmaceuticals Inc

ThromboGenics NV

## I would like to order

Product name: Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Pipeline Review, H1 2018

Product link: <https://marketpublishers.com/r/PEE54C94F35EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PEE54C94F35EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

